When was Cingulate founded?

Cingulate was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is Cingulate located?

Cingulate is headquartered in Kansas City, United States.

Who is the current CEO of Cingulate?

Shane J Schaffer of Cingulate. They have also founded 1 company.

How many employees does Cingulate have?

As of Aug 31, 2026, the latest employee count at Cingulate is 22.

Is Cingulate a funded company?

Cingulate is a funded company, having raised a total of $33M across 6 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Nov 14, 2013.

When was the latest funding round of Cingulate?

Cingulate's latest funding was a $***** Post IPO round on Jul 22, 2025, with participation from 1 investor.

Where does Cingulate rank among its competitors?

Cingulate ranks 3rd amongst 110 active competitors, of which 28 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Connecta Therapeutics, which secured $3.61M in Sep, 2026.

Who are the top competitors of Cingulate?

Cingulate's top competitors include Cure Pharmaceutical, Nura Bio and SciNeuro. Among them, Connecta Therapeutics secured the most recent funding round in September, 2026.

Cingulate - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the treatment of ADHD. The product CTx-1301 has dexmethylphenidate and CTx-1302 has dextroamphetamine formulation which utilizes the company's precision timed-release drug delivery platform. The platform has an erodible barrier layer that helps in controlled drug release.

Website: cingulate.com
Social
Email ID: *****@cingulate.com
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

Kansas City, United States

Stage

Public

Total Funding

$33M in 6 rounds

Latest Funding Round

Post IPO, Jul 22, 2025, $*****

Investors

The Werth Family Foundation & 3 more

Ranked

3^rd among 110 active competitors

Employee Count

22 as on Aug 31, 2026

Similar Companies

Cure Pharmaceutical & 111 more

Exit Details

Public

View Cingulate's full profile

Cingulate is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CINGULATE INC. CIN: 1862150 , United States, Active	May 09, 2021	-	-	-
Cingulate Therapeutics, LLC CIN: 46-1470260 , United States, Active	Nov 13, 2012	-	17 (As on Dec 31, 2021)	-

Cingulate got listed on Dec 08, 2021.

Click here to take a look at Cingulate's IPO in detail

Cingulate has raised a total funding of $33M over 6 rounds. Its first funding round was on Nov 14, 2013. Its latest funding round was a Post IPO round on Jul 22, 2025 for $*****. 1 investor participated in its latest round. Cingulate has 4 institutional investors.

Here is the list of recent funding rounds of Cingulate:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 22, 2025	7869495	Post IPO	2757567	1951474	4626522	2390281
Apr 09, 2025	9506249	Grant (prize money)	9972570	6852524	6143526	6159639
Jan 12, 2024	2163134	Post IPO	8809372	5279979	6357589	6191352

Access funding benchmarks and valuations. Sign up today!

View details of Cingulate's funding rounds and investors

The founders of Cingulate is Shane J Schaffer. Shane J Schaffer is the CEO of Cingulate.

Here are the details of Cingulate's key team members:

Shane J Schaffer: Co-Founder & CEO of Cingulate.

View details of Cingulate's Founder profiles and Board Members

Cingulate's employee count trend

Cingulate has 22 employees as of Aug 26. Here is Cingulate's employee count trend over the years:

Uncover Cingulate's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cingulate include Cure Pharmaceutical, Nura Bio and SciNeuro. Here is the list of Top 10 competitors of Cingulate, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cure Pharmaceutical 2010, Oxnard (United States), Public	Developer of oral thin film based drug delivery systems	$9.65M	Onbelay Capital, Hangar202 & 1 others	62/100
2nd	Nura Bio 2018, San Francisco (United States), Series B	Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines	$215M	The Column Group, Sanofi Ventures & 2 others	59/100
3rd	Cingulate 2012, Kansas City (United States), Public	Developer of therapeutics for the treatment of ADHD	$33M	Lincoln Park Capital, The Werth Family Foundation ... & 2 others	58/100
4th	SciNeuro 2020, Shanghai (China), Series A	Developer of therapeutic solutions for the treatment of CNS disorders	$153M	Arch Venture Partners, LAV & 6 others	55/100
5th	Vivtex 2018, Cambridge (United States), Seed	Developer of oral drug delivery system	$1.8M	-	53/100
6th	Connecta Therapeutics 2018, Barcelona (Spain), Series A	Developer of drugs for treating neurological disorders	$8.5M	Inveready, CDTI & 6 others	52/100
7th	Oramed 2006, Jerusalem (Israel), Public	Developer of oral reformulations to treat various health conditions	-	EIC Fund, Europa	51/100
8th	PLx Pharma 2002, Sparta (United States), Public	Developer of drug delivery platform to treat gastrointestinal diseases	$25.3M	Aurus, HHS	49/100
9th	Metispharma 2020, Hangzhou (China), Series D	Developer of AI-driven nanomedicine platforms for targeted drug delivery systems	$55.5M	Daxing Industrial Investment Fund, Beijing Medical and Health Industry Investment Fund ... Read more	49/100
10th	Ingenus 2010, Orlando (United States), Unfunded	Developer of oral drug delivery and drugs for treating cancer	-	-	49/100